Tenax Therapeutics Appoints Gillian Andor as VP of Clinical Operations to Bolster Phase 3 Program
Key Insights
Tenax Therapeutics has appointed Gillian Andor as Vice President of Clinical Operations to support its Phase 3 program for oral levosimendan (TNX-103).
Ms. Andor brings over 20 years of experience in clinical operations, including NDA submissions and approvals, to accelerate the Phase 3 LEVEL study.
Her expertise will be crucial as Tenax Therapeutics advances oral levosimendan for pulmonary hypertension due to heart failure with preserved ejection fraction (search) (PH-HFpEF).
Tenax Therapeutics, Inc. (Nasdaq: TENX) has announced the appointment of Gillian Andor, MSc, as Vice President of Clinical Operations. Effective January 22, 2025, Ms. Andor will spearhead the company's clinical operations, focusing on the Phase 3 program evaluating oral levosimendan (TNX-103) for treating pulmonary hypertension due to heart failure with preserved ejection fraction (search) (PH-HFpEF).
Andor's Extensive Experience
Ms. Andor brings over two decades of experience in clinical operations to Tenax Therapeutics. Before joining Tenax, she served as Interim Head of Clinical Development Operations at Noema Pharma (search), concentrating on CNS disorders. She also held the position of Head of Portfolio Operations at Sage Therapeutics, where she played a pivotal role in the successful NDA submissions and approvals for Zulresso® and Zurzuvae®, medications for postpartum depression. Her prior experience includes roles at Ironwood Pharmaceuticals, where she contributed to the NDA and approval of Linzess® for IBS-C (search).
Leadership's Perspective
"We are pleased to welcome Gillian to the Tenax team at a critical time for our Company, as we continue to enroll patients in the Phase 3 LEVEL study and finalize plans to initiate our second pivotal study," stated Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. "We believe Gillian’s significant experience executing clinical development programs resulting in NDA submissions and approvals will help us accelerate our Phase 3 program and ensure we are prepared for global regulatory filings."
Focus on Levosimendan
Tenax Therapeutics is currently focused on developing and commercializing products for cardiovascular and pulmonary diseases with significant unmet medical needs. The company owns the global rights to levosimendan and is prioritizing its development. Levosimendan is being investigated as a potential treatment for PH-HFpEF, a condition with limited therapeutic options. The ongoing Phase 3 LEVEL study is designed to evaluate the efficacy and safety of oral levosimendan in this patient population.
Equity Award
In connection with her appointment, Tenax Therapeutics issued Ms. Andor an inducement equity award consisting of an option to purchase 250,000 shares of the company’s common stock. The award vests in four equal annual installments, contingent upon her continued employment. The exercise price for the option is $6.44. This award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).